BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Etzer Darout does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 QTTBQ32 Bio Inc | Buy | $22.00 | Dec 2024 | −31.2% | Miss |
| QTTBQ32 Bio Inc | Buy | $64.00 | Dec 2024 | −91.3% | Miss |
 ACRVAcrivon Therapeutics, Inc. Common Stock | Buy | $27.00 | Nov 2024 | −76.8% | Miss |
 NUVLNuvalent Inc | Buy | $134.00 | Nov 2024 | −2.6% | Miss |
 GMABGenmab AS | Buy | $48.00 | Nov 2024 | +24.8% | Miss |
 XNCRXencor Inc | Buy | $34.00 | Nov 2024 | −41.5% | Miss |
| ACRVAcrivon Therapeutics, Inc. Common Stock | Buy | $28.00 | Sep 2024 | −69.1% | Miss |
| XNCRXencor Inc | Buy | $32.00 | Aug 2024 | −43.2% | Miss |
 CCCCC4 Therapeutics Inc | Buy | $20.00 | Aug 2024 | −57.1% | Miss |
| XNCRXencor Inc | Buy | $32.00 | Jun 2024 | −48.3% | Miss |
| ACRVAcrivon Therapeutics, Inc. Common Stock | Buy | $25.00 | May 2024 | −77.9% | Miss |
 AZNAstraZeneca PLC | Buy | $82.00 | Apr 2024 | −5.7% | Hit |
| ACRVAcrivon Therapeutics, Inc. Common Stock | Buy | $25.00 | Apr 2024 | −84.8% | Miss |
| ACRVAcrivon Therapeutics, Inc. Common Stock | Buy | $18.00 | Apr 2024 | −75.9% | Miss |
| AZNAstraZeneca PLC | Buy | $80.00 | Feb 2024 | +17.9% | Hit |
| CCCCC4 Therapeutics Inc | Buy | $16.00 | Nov 2023 | +240.1% | Miss |
| AZNAstraZeneca PLC | Buy | $82.00 | Jan 2023 | −5.6% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.